Aurora Cannabis (NASDAQ:ACB) Announces Quarterly Earnings Results, Beats Estimates By $999.07 EPS

Aurora Cannabis (NASDAQ:ACB) released its quarterly earnings data on Thursday. The company reported $999.00 earnings per share for the quarter, beating the consensus estimate of ($0.07) by $999.07, Zacks reports. Aurora Cannabis had a negative return on equity of 0.04% and a negative net margin of 23.46%.

Aurora Cannabis Stock Performance

Aurora Cannabis stock opened at $3.29 on Thursday. Aurora Cannabis has a fifty-two week low of $3.07 and a fifty-two week high of $6.66. The stock has a fifty day moving average of $3.46 and a two-hundred day moving average of $3.85. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.48 and a current ratio of 3.06. The company has a market capitalization of $201.82 million, a price-to-earnings ratio of -3.05 and a beta of 0.53.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Weiss Ratings raised Aurora Cannabis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 1st. Wall Street Zen raised Aurora Cannabis from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Aurora Cannabis currently has a consensus rating of “Hold”.

Institutional Investors Weigh In On Aurora Cannabis

Several hedge funds have recently made changes to their positions in the business. Tidal Investments LLC boosted its holdings in shares of Aurora Cannabis by 6.0% during the second quarter. Tidal Investments LLC now owns 1,509,483 shares of the company’s stock worth $6,400,000 after purchasing an additional 86,045 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of Aurora Cannabis by 7,412.0% during the third quarter. Two Sigma Investments LP now owns 1,149,869 shares of the company’s stock worth $6,853,000 after purchasing an additional 1,134,562 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Aurora Cannabis by 4.1% during the first quarter. Goldman Sachs Group Inc. now owns 743,903 shares of the company’s stock worth $3,266,000 after purchasing an additional 29,099 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Aurora Cannabis by 563.7% during the third quarter. Millennium Management LLC now owns 391,782 shares of the company’s stock worth $2,339,000 after purchasing an additional 332,750 shares during the last quarter. Finally, UBS Group AG boosted its holdings in shares of Aurora Cannabis by 136.8% during the third quarter. UBS Group AG now owns 184,190 shares of the company’s stock worth $1,098,000 after purchasing an additional 106,391 shares during the last quarter. Institutional investors and hedge funds own 47.63% of the company’s stock.

About Aurora Cannabis

Aurora Cannabis Inc (NASDAQ: ACB) is a Canadian licensed producer of medical and consumer cannabis products headquartered in Edmonton, Alberta. Established in 2013, the company operates under Health Canada’s regulations to cultivate, process and distribute a range of cannabis-based offerings. Since its initial public listing in 2017, Aurora has grown into one of the country’s largest growers by cultivation capacity and production output.

The company’s core business spans the cultivation of dried flower, the extraction of cannabis oils and the development of value-added products such as softgels, capsules and topical treatments.